Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Apollo Global Management Ord Shs (APO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Apollo Global Management Ord Shs — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Apollo Global Management Ord Shs trades at $118.11 (market cap $68.80B). The key difference: Apollo Global Management Ord Shs is far larger — about 15.3× ACADIA Pharmaceuticals Inc.'s market cap, and Apollo Global Management Ord Shs pays a 1.89% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | APO | |
|---|---|---|
Market Cap | $4.49B | $68.80B |
Sector | Health | Financials |
52-Week High | $28.06 | $156.05 |
52-Week Low | $20.06 | $100.30 |
Enterprise Value | $3.69B | -$168.77B |
Dividend Yield | — | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Apollo Global Management (APO) trades at $119.33, up 0.61% with a bearish technical signal despite strong analyst consensus. The company reported Q1 2026 EPS of $1.94, beating expectations, and maintains a 95.15% gross margin. Recent news highlights liquidity pressures in private credit funds, with Apollo capping withdrawals from its $25 billion Apollo Debt Solutions fund after 17% redemption requests in Q2 2026.
Outlook remains mixed: strong fee-generating AUM growth and dividend increases support bullish analyst targets averaging $149.71, but near-term risks include private credit liquidity concerns and multiple law firm investigations. The stock offers 25% upside to consensus target if liquidity pressures ease and earnings meet guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →
